INO

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a biotechnology company founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania. The company went public in 1998 and has spent over four decades developing DNA-based medicines to treat diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Inovio is currently focused on advancing its lead product candidate INO-3107 toward commercialization, with plans to submit a Biologics License Application to the FDA in mid-2025 for treating recurrent respiratory papillomatosis, a rare HPV-related condition.